Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label

With long-term administration, the most frequent (occurring in ≥ 5% of patients) treatment-emergent adverse events, regardless of whether such adverse event was related to treatment, were decrease in weight (9.5%), dry mouth (7.6%), diarrhea (7.0%), and headache (5.1%). The proportion of patients experiencing motor side effects while on lumateperone was low: any adverse event related to extrapyramidal side effects combined including akathisia (5.3%); and akathisia specifically (0.5%). There were no signs of treatment-emergent extrapyramidal side effects, akathisia, or dyskinesia as measured by the Simpson Angus Scale (SAS), the Barnes Akathisia Rating Scale (BARS), or the Abnormal Involuntary Movement Scale (AIMS), respectively. In addition, there were no signs of treatment-emergent suicidal ideation or behavior as measured by the Columbia-Suicide Severity Rating Scale (C-SSRS).


No such thing as a side effect free med I guess…

I mean placebo isn’t side effect free so…


Weight loss? That’s great.

1 Like

Lets just hope the weight loss doesnt make you dependent on sugar diabetic type 1.

Funny you mention that. lumateperone didn’t perform better than placebo in phase 3 ! :grinning:

1 Like

While none of these side effects sound like fun, at least they’re relatively minor and treatable.

1 Like

Its kinda funny for me to know that it decrease in body weight. ‘‘As a side-effect’’.

For % or so of people.

Correcting myself:

Of the 603 patients in the trial, 24% experienced a decrease of ≥ 7% from their SOC baseline body weight over the course of the study, whereas only 8% experienced a body weight increase of ≥7%.

But yeah, for many people this would be a benefit, not a (negative) side effect.

Well, yeah for me it would be good to be on Lumateperone, ive always been with Olanzapine, almost died once on Invega Sustenna, trying to explain to the doctor with extreme akathisia, the heart ache.

1 Like

How do I buy stock